Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18746808 | UNGLYCOSYLATED LYSOSTAPHIN VARIANT PROTEIN | June 2024 | March 2026 | Allow | 20 | 1 | 1 | No | No |
| 18662758 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | May 2024 | January 2026 | Allow | 20 | 1 | 1 | No | No |
| 18315466 | RECOMBINANT NEPROSIN POLYPEPTIDES AND METHODS OF EXPRESSION | May 2023 | February 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18033822 | FUSOBACTERIUM BACTERIOPHAGE AND USES THEREOF | April 2023 | February 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18115752 | COMPOSITION OF LACTIC BACTERIA FOR USE IN THE TREATMENT OF INFECTIONS DUE TO PROPIONIBACTERIUM ACNES AND IN PARTICULAR FOR ACNE | February 2023 | September 2025 | Abandon | 31 | 4 | 0 | No | No |
| 18007300 | DEVELOPMENT OF A NEW ENGINEERED TOBACCO ETCH VIRUS (TEV) PROTEASE ACTIVABLE IN THE CYTOSOL OR SECRETORY PATHWAY | January 2023 | January 2026 | Abandon | 36 | 1 | 1 | No | No |
| 18097096 | VIRAL VECTORS FOR TREATING PARKINSON'S DISEASE | January 2023 | March 2026 | Allow | 38 | 1 | 0 | No | No |
| 17910688 | NEW RECOMBINANT LYSIN AND ITS USE IN THE TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTIONS | September 2022 | February 2026 | Allow | 41 | 2 | 1 | Yes | No |
| 17773233 | METHOD FOR TREATING CANCER | April 2022 | June 2025 | Allow | 38 | 1 | 1 | No | No |
| 17658566 | INTEGRATED FERMENTATION AND ELECTROLYSIS PROCESS FOR IMPROVING CARBON CAPTURE EFFICIENCY | April 2022 | February 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17580513 | METHODS OF DETECTING GLYCOGEN AND POLYGLUCAN | January 2022 | February 2026 | Abandon | 49 | 4 | 1 | Yes | No |
| 17417266 | BIOLOGICAL MICROBIAL TREATING AGENT FOR RADIOACTIVE MATERIAL REMOVAL | June 2021 | January 2026 | Abandon | 55 | 2 | 1 | No | No |
| 17256523 | FIXABLE VIABILITY DYES AND THEIR USES | December 2020 | December 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 14894347 | COMPOSITIONS AND METHODS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES | November 2015 | September 2017 | Allow | 22 | 2 | 0 | Yes | No |
| 14648804 | PLATELET CONCENTRATE PRESERVATION METHOD | June 2015 | May 2017 | Allow | 23 | 1 | 1 | No | No |
| 14618713 | DETECTION DEVICE AND MANUFACTURING METHOD FOR THE SAME | February 2015 | December 2016 | Allow | 22 | 2 | 0 | No | No |
| 14008538 | Immunosuppressive Cell-Capturing Material and Immunosuppressive Cell-Capturing Column | September 2013 | June 2015 | Allow | 20 | 1 | 0 | No | No |
| 13942827 | METHODS FOR PROMOTING NEURONAL DEVELOPMENT AND/OR HEALTH | July 2013 | August 2015 | Allow | 25 | 1 | 0 | No | No |
| 13637459 | ZEODRATION METHOD FOR THE PRESERVATION OF BLOOD PLATELETS | December 2012 | April 2014 | Allow | 18 | 2 | 0 | No | No |
| 13703149 | DEVICE FOR RAPIDLY DETECTING MICROORGANISMS | December 2012 | May 2014 | Allow | 17 | 2 | 0 | Yes | No |
| 13643115 | METHOD AND DEVICE FOR VISUAL DETECTION OF HEMOLYSIS | October 2012 | March 2014 | Allow | 16 | 2 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner PAPCIAK, SHARON M works in Art Unit 1657 and has examined 10 patent applications in our dataset. With an allowance rate of 90.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner PAPCIAK, SHARON M's allowance rate of 90.0% places them in the 73% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by PAPCIAK, SHARON M receive 1.90 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PAPCIAK, SHARON M is 22 months. This places the examiner in the 88% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +16.7% benefit to allowance rate for applications examined by PAPCIAK, SHARON M. This interview benefit is in the 57% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
Examiner's Amendments: This examiner makes examiner's amendments in 10.0% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.